Sosei And NeuroSolutions Present Further Data On NSL-043/SD118 At The Society For Neuroscience 38th Annual Meeting

 20.11.2008 04:08   medicalnewstoday.com

NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience service provider and drug development Company, and Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a leading international biopharmaceutical company, announce that NeuroSolutions is presenting further pivotal pre-clinical efficacy data for NSL-043/SD118. This investigational drug is a potential therapy for neuropathic pain and has successfully completed Phase I clinical studies and is now ready for Phase II studies.

World Neurology